APRAMEYA vs DRAGARWQ: Stock Comparison
DR. AGARWAL'S EYE HOSP L is the larger company by market capitalisation. APRAMEYA shows lower leverage, while DR. AGARWAL'S EYE HOSP L shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
APRAMEYA leads 4; DRAGARWQ leads 7 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Price
| Metric | APRAMEYA | DRAGARWQ |
|---|---|---|
| Live Price | — | ₹5,371.5 |
| Day Change | — | 2.22% |
| Volume | — | 708 |
| 52-Week High | — | ₹6,059.7 |
| 52-Week Low | — | ₹4,600 |
| Distance from 52W High | — | -11.36% |
Valuation
| Metric | APRAMEYA | DRAGARWQ |
|---|---|---|
| Market Cap | ₹217 Cr | ₹2,600 Cr |
| P/E Ratio | 60.82x | 34.11x |
| P/B Ratio | 0x | 7.51x |
| EPS | ₹2.68 | ₹48.38 |
| Book Value | ₹36.54 | ₹716.56 |
| Dividend Yield | 0% | 0.13% |
Growth
| Metric | APRAMEYA | DRAGARWQ |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 0% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | 0.7% | -69.64% |
| Qtr Profit Growth | 1.73% | -66.65% |
Profitability & Leverage
| Metric | APRAMEYA | DRAGARWQ |
|---|---|---|
| ROE | 7.37% | 20.24% |
| ROCE | 10.07% | 18.74% |
| Net Margin | 0% | 14.89% |
| Operating Margin | 19.83% | 22.4% |
| Debt to Equity | 0.1x | 0.24x |
Shareholding
As of Mar 2026 • change vs previous quarter| Metric | APRAMEYA | DRAGARWQ |
|---|---|---|
| Promoter Holding | 74.05%▲ 0.52 pp | 72.67% |
| FII Holding | 0% | 2.24%▲ 0.04 pp |
| DII Holding | 0.7%▼ 0.07 pp | 2.05%▼ 0.07 pp |
| Public Holding | 25.24%▼ 0.46 pp | 23.04%▲ 0.04 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: APRAMEYA and DR. AGARWAL'S EYE HOSP L.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.